Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Personalized Medicine Biomarkers Industry By 2029?

The market size for personalized medicine biomarkers has seen substantial growth in recent times. It is projected to increase from $22.85 billion in 2024 to $26.73 billion in 2025, with a compound annual growth rate (CAGR) of 17.0%. The growth experienced in the previous period is due to the rising occurrence of chronic illnesses, increased usage of companion diagnostics, growing funding dedicated for biomarker research, an increased emphasis on early diagnostic measures and preventive healthcare, as well as regulatory encouragement for therapies based on biomarkers.

In the coming years, the market size of personalized medicine biomarkers is set to experience substantial growth, reaching $50.33 billion in 2029 with a compound annual growth rate (CAGR) of 17.1%. The forecasted growth can be linked to numerous factors including the widening applications in precision oncology, rising demand for targeted treatments, increasing emphasis on early disease identification, growing consumer preference for personalized treatments, and supportive government initiatives and funds. Key trends anticipated during this forecasted period encompass a multi-omics approach to identify biomarkers, the evolution of liquid biopsy-based biomarkers development, the growing application of digital biomarkers, the increased use of AI and machine learning in the discovery of biomarkers, and the broadening use of real-world evidence for biomarker verification.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Which Industry Forces Are Driving The Personalized Medicine Biomarkers Market Forward?

The surge in chronic diseases is predicted to fuel the expansion of the personalized medicine biomarkers market. Chronic diseases are slow-progressing, long-term health conditions that last over a year and require consistent medical care or impact daily activities. This surge is attributed to unhealthy lifestyle choices, poor diets, lack of physical activity, and elevated stress levels. Personalized medicine biomarkers facilitate tailored treatments for chronic diseases by pinpointing effective therapies, anticipating disease progression, and reducing unfavourable effects based on personalized genetic and molecular profiles. For example, the World Health Organization (WHO), a Switzerland-based health authority, stated in February 2024 that the number of new cancer cases is anticipated to exceed 35 million by 2050, indicating a 77% surge from the projected 20 million cases in 2022. Hence, the surge in chronic diseases is propelling the personalized medicine biomarkers market’s expansion.

How Is The Personalized Medicine Biomarkers Market Organized By Different Segments?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Current And Upcoming Trends Are Shaping The Personalized Medicine Biomarkers Market?

Key enterprises in the personalized medicine biomarkers sector are concentrating their efforts on securing regulatory authorizations. This strategy is aimed at boosting the reputation of their products, enlarging their market share, and advancing patient outcomes. Regulatory approvals are endorsements from health entities, attesting that a medical product, procedure, or technology adheres to safety, effectiveness, and quality standards for public use. For example, in August 2024, Illumina, Inc., a US-based biotech firm, was granted approval by the Food and Drug Administration (FDA) for its cancer biomarker examination and a pair of companion diagnostics. The test implements next-generation sequencing (NGS) technology to detect genetic anomalies in cancer cells, thereby assisting healthcare professionals in choosing the optimal treatments based on individual biomarkers. This clearance represents a vital progress in precision oncology, striving to elevate the efficiency and precision of treatment choice for cancer patients, ultimately promoting personalized healthcare.

Which Firms Are Making The Biggest Impact In The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Dominates The Personalized Medicine Biomarkers Market Today?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model